David B. Horton, Ph.D.
Affiliations: | Pharmaceutical Sciences | University of Kentucky, Lexington, KY |
Area:
Drug and alcohol abuseGoogle:
"David Horton"Mean distance: 17.56 (cluster 6) | S | N | B | C | P |
Parents
Sign in to add mentor| Linda P. Dwoskin | grad student | 2012 | University of Kentucky | |
| (Discovery of GZ-793A, a novel VMAT2 inhibitor and potential pharmacotherapy for methamphetamine abuse.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Nickell JR, Siripurapu KB, Horton DB, et al. (2016) GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. European Journal of Pharmacology. 795: 143-149 |
| Beckmann JS, Meyer AC, Pivavarchyk M, et al. (2015) r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research |
| Wager TT, Chandrasekaran RY, Bradley J, et al. (2014) Casein kinase 1δ/ε inhibitor PF-5006739 attenuates opioid drug-seeking behavior. Acs Chemical Neuroscience. 5: 1253-65 |
| Horton DB, Nickell JR, Zheng G, et al. (2013) GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine. Journal of Neurochemistry. 127: 177-86 |
| Horton DB, Potter DM, Mead AN. (2013) A translational pharmacology approach to understanding the predictive value of abuse potential assessments. Behavioural Pharmacology. 24: 410-36 |
| Narayanaswami V, Somkuwar SS, Horton DB, et al. (2013) Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release. Biochemical Pharmacology. 86: 656-65 |
| Zheng G, Horton DB, Penthala NR, et al. (2013) Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse. Medchemcomm. 4: 564-568 |
| Horton DB, Siripurapu KB, Zheng G, et al. (2011) Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal of Pharmacology and Experimental Therapeutics. 339: 286-97 |
| Meyer AC, Horton DB, Neugebauer NM, et al. (2011) Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration. Neuropharmacology. 61: 849-56 |
| Horton DB, Siripurapu KB, Norrholm SD, et al. (2011) meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal of Pharmacology and Experimental Therapeutics. 336: 940-51 |